Release date: 2006-12-08
The United States has found that supermorphic enzymes enhance the body's ability to fight cancer. American researchers have found that the Akt1 enzyme has a "super" form that enhances the anti-cancer effect by extending the lifespan of dendritic cells, which scientists have long believed. Dendritic cells are the main "switches" in the immune system that respond to T cells that have anti-cancer capabilities. The research report was published in the recently published journal Nature Science.
Dr. David Spencer, Ph.D., associate professor of immunology at Baylor College of Medicine, said: "By extending the lifespan of dendritic cells, it can prolong the activation of the body and promote the immune response that people need." It is believed that "dendritic cells are the main switch in the immune system. In the face of pathogens or cancer, they can decide whether to take a strong immune response or a mild immune response."
Through a variety of complex experiments, Spencer and colleagues found that Akt1 enzyme plays an important role in the survival of dendritic cells. Immediately, they found a more efficient form of the Akt1 enzyme. This form of the Aktl enzyme can help dendritic cells survive longer and thus promote an immune response.
To obtain a new form of the Akt1 enzyme, the researchers first modified the Akt1 enzyme to allow them to lock in specific locations on the plasma cell membrane, which gave the Aktl enzyme a clearer behavior. They then removed a small portion of the inhibitory molecule of the Akt1 enzyme. Spencer said that the "super" Akt1 enzyme obtained after transformation is more effective.
After obtaining the "super" Akt1 enzyme, the researchers used a specially designed adenovirus to deliver it into dendritic cells. "As expected, these dendritic cell lifespans are extended and more effective, both in laboratory vessels and in experimental mice," Spencer said. "It causes some of the mice to have some Aggressive tumors are eliminated."
In the lab, the researchers also found that the "super" Akt1 enzyme is equally effective against human dendritic cells, but they have not yet used it to treat human diseases. Spencer hopes that the first target of Akt1 enzyme in humans is prostate cancer, because this is a subject that their laboratory has been studying for a long time. He also said that the Aktl enzyme can also be used to cope with other cancers.
—— Information from: Science and Technology Daily
Starch Noodle Machine,Electric Noodle Machine,Starch Noodle Making Machine,Potato Starch Noodle Machine
Shuangfeng County Dingyuan Machinery Manufacturing Co. Ltd.. , https://www.separators.pl